Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,592.50
Bid: 1,591.50
Ask: 1,592.50
Change: -12.00 (-0.75%)
Spread: 1.00 (0.063%)
Open: 1,613.00
High: 1,613.00
Low: 1,591.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

Mon, 12th Feb 2024 12:04

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

The FTSE 100 index fell 11.34 points, 0.2%, at 7,561.24. The FTSE 250 is up 74.94 points, 0.4%, at 19,137.26, and the AIM All-Share added 1.39 points, 0.2%, at 748.80.

The Cboe UK 100 fell 0.1% to 755.81, the Cboe UK 250 climbed 0.7% to 16,572.23, but the Cboe Small Companies fell 0.3% to 14,497.62.

The CAC 40 in Paris and Frankfurt's DAX 40 were both 0.3% higher.

Stocks in New York are set for a muted open. The Dow Jones Industrial Average is called down 0.1%, the S&P 500 flat and the Nasdaq Composite a touch higher.

"Investors are hanging onto every word uttered by anyone affiliated with the major central banks, looking for signs that interest rate cuts are finally on the agenda," AJ Bell analyst Russ Mould commented.

"Expectations that we will soon see this pivot moment have underpinned the pick-up in equity markets since late 2023 and confirmation of the first cut could give another leg-up to stocks and shares. The new trading week saw the spotlight shun on European stocks after ECB Governing Council member Fabio Panetta said the magic moment is 'fast approaching' for the European Central Bank to reduce rates."

The pound was quoted at USD1.2614 early Monday afternoon, down from USD1.2632 late on Friday. The euro stood at USD1.0768, down from USD1.0783. Against the yen, the dollar was trading at JPY149.03, down from JPY149.31.

ING analyst Francesco Pesole commented: "The second-best performing currency after the USD of 2024, the pound, is about to face a couple of key data tests this week. Tomorrow, jobs data for January is released, and Wednesday sees the CPI report and Thursday GDP data.

"Our economics team sees both wage growth and services inflation remaining sticky in the first quarter, meaning that the Bank of England will have no rush to turn to a more dovish communication in the near future. Markets are expecting the BoE to move with a delay (in August) compared to the ECB's and Fed's easing cycles. We agree, but also see 100bp (vs 80bp priced in) of cuts by year-end. Some GBP weakness against the EUR down the road is therefore our base case, but the short-term outlook remains quite constructive for sterling."

It will also be a key week for oil markets. Crude prices were on the decline on Monday, however.

Brent oil was quoted at USD81.16 a barrel early Monday afternoon in London, down from USD82.03 late Friday.

Scope Markets analyst Joshua Mahony commented: "This week sees both Opec and the IEA release their latest monthly reports, with markets keeping a close eye out for any updated supply and demand forecasts. Thus far we have seen the record US output keep a lid on global oil prices, with markets casting aside the historic disruptions to global trade through the Red Sea. However, the recent Saudi decision to reverse the planned 1 million bpd production increase from Aramco highlights the continued efforts to support prices in an oversupplied market. While some will hope that we will soon see a stimulus-led resurgence in Chinese economic activity, we are yet to see any tangible signs of a bounceback that might lift assets such as oil."

Gold fetched USD2,021.68 an ounce, flat from USD2,021.73.

In London, share price falls for pharmaceutical firms put pressure on the FTSE 100. GSK and AstraZeneca, two index heavyweights, fell 0.9% and 1.7%.

AstraZeneca shares came into the week on a three-day losing streak, including a more than 6% slide on the day it released annual results.

"We think this presents a compelling entry point for a best-in-class company," analysts at Barclays said on Monday, however.

NatWest shares fell 2.3%. The lender reports annual results on Friday.

AJ Bell's Mould added: "The UK corporate reporting calendar is fairly quiet until Thursday when Relx and Centrica issue results, followed by NatWest on Friday. In the US, Coca-Cola reports on Tuesday, Cisco on Wednesday and Deere & Co and Applied Materials on Thursday. That's enough to keep investors on their toes."

Tritax Big Box REIT fell 3.2%, while UK Commercial Property REIT added 5.2%, as the duo announced they have agreed to indicative terms for a tie-up.

It will create the UK's fourth-largest real estate investment trust by market capitalisation, at nearly GBP4 billion.

UKCM investors stand to receive 0.444 of a new Tritax Big Box share for every UKCM share they own.

Based on Tritax Big Box's closing share price on Friday, the deal would value each UKCM share at 71.1 pence and the full company's equity at GBP924 million.

The announcement by the two FTSE 250 index constituents represents the latest in a series of mergers of London-listed property companies since the year began. LondonMetric Property and LXi REIT also agreed an all-share merger. Custodian Property Income REIT and abrdn Property Income Trust also struck a deal.

RBC Brewin Dolphin said the Tritax Big Box-UKCM deal is the latest indicator of a "more investible future for UK property", expecting more deals to be announced across 2024 "as more REITs and property companies adapt to higher interest rates and reassess their portfolios amid huge changes in the way property is used."

"At their current scale, the UK's REITs are limited by their size – this has an effect on the capital they can attract, the terms on which they can borrow, and ultimately the deals they can do. Combine them all and you have just one of the main North American property asset managers – they simply can't compete on a global scale," said RBC Brewin Dolphin analyst John Moore.

Galliford Try has landed a place in a GBP3.2 billion affordable homes framework in the UK.

The construction firm said it has won a place on lot 2 of an eight-year Communities & Housing Investment Consortium framework worth GBP2.5 billion, and lot 3, which is worth GBP650 million. Lot 2 includes new build projects and Lot 3 regeneration work.

Galliford shares rose 4.5%.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.